Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
We endeavour to be the global voice of the generic and biosimilar medicines industries and, while promoting the highest GMP and GCP standards, cooperate to remove trade barriers that hinder commercial distribution of medicines across regional and international boundaries.
Promote regulatory cooperation and convergence of requirements for approval of generic and biosimilar medicines through international regulatory conferences /fora and trade negotiations.
Promote the widest possible access of medicines with high quality, safety and efficacy to patients globally.
Promote intellectual property regimes which foster innovation and allow timely launch of generic and biosimilar medicines, while supporting fair competition and preventing risks of IP abuses globally.
Be a representative body for global Generic and Biosimilar industries by attracting the widest assembly of members who are committed to subscribing to our standards and principles.
Represent our members and support and co-operate with relevant international bodies and initiatives including the WHO, WTO, WIPO, ICH, IGDRP, IPRF, etc.
Support parties in international and regional agreement negotiations to remove barriers and facilitate the registration and supply of generic and biosimilar medicines.
Foster the sustainability of medicine manufacturers in the interests of healthcare systems and patients.
Advance better access to generic and biosimilar medicines globally by organizing international conferences for the industry, stakeholders and regulators.